The Hook: Hair-Growth Peptides Finally Got a Report Card
Search "peptides for hair loss" and you'll find serums with big promises and not much proof. A new systematic review in the Journal of Drugs in Dermatology (Joerg, Zafar and Jagdeo, 2026) is one of the more useful sorting efforts so far. It screened the human clinical literature and graded what held up. Three names came out on top, along with one lesser-known peptide: acetyl tetrapeptide-3, biotinoyl tripeptide-1, and GHK (the "copper peptide" family).
The grades are encouraging but modest, and the fine print matters.
How the Review Worked
The authors searched PubMed, Embase and the Cochrane Library on November 3, 2025, following PRISMA reporting guidelines. They looked for English-language clinical trials of peptide-containing therapies for hair loss in human subjects.
- 981 studies were identified.
- 14 trials met the inclusion criteria.
- Each peptide or formulation received a grade of recommendation.
The abstract reports two tiers:
- Grade B: formulations with acetyl tetrapeptide-3, biotinoyl tripeptide-1, glycyl-histidyl-lysine (GHK) peptide, and the penta-peptide Gly-Pro-Ile-Gly-Ser.
- Grade C: QR678 and QR678 Neo®.
In most evidence-grading systems, B means reasonable but limited or inconsistent evidence, and C is weaker. Neither is the top tier. Grade B is not "proven," and it is not the kind of evidence behind long-established hair-loss drugs. The abstract doesn't spell out the grading scale, so check the full paper for the exact criteria.
The Peptides That Scored Best
Acetyl tetrapeptide-3 (often sold as Capixyl)
This is a short, lab-made peptide used in cosmetic hair serums. Commercial versions are often blended with plant-derived ingredients. It was one of the ingredients the authors singled out in their conclusion.
Biotinoyl tripeptide-1 (often sold as Procapil)
This is a peptide linked to biotin, the B vitamin people associate with hair. It is also a common ingredient in "hair density" serums, and the review gave it the same grade B.
GHK, the copper peptide (GHK-Cu)
GHK (glycyl-histidyl-lysine) is a small peptide best known in its copper-bound form. It has a long history in skincare and has more name recognition than the other two. It shares the grade B tier and is the third ingredient the authors highlighted.
The fourth Grade B entry
The penta-peptide Gly-Pro-Ile-Gly-Ser also earned a B. It gets far less attention in consumer products, and the abstract says little about it.
QR678 and QR678 Neo®
These got a C. QR678 is a branded formulation rather than a single peptide, and it generally appears in clinic-based treatment protocols rather than drugstore serums. The abstract doesn't describe how it was delivered in the included trials, so check the full text before drawing conclusions.
Topicals, Not Injections (Mostly)
The first three ingredients are mainly used in topical formulations such as serums, lotions and scalp products. That fits how they appear in the market, though the abstract itself says only "formulations." This is not the injectable-peptide scene you see in some wellness circles. The review covers peptide-containing hair products, not unregulated injectables, and it offers no evidence on those.
The Honest Limits
The paper's conclusion is positive, calling peptide formulations "effective, well-tolerated alternatives to conventional hair-growth therapies." Several caveats apply.
- The pool is small. Fourteen trials across several different peptides means thin evidence for each one. The abstract doesn't report sample sizes, so I can't say how large the individual trials were. Given the grade B and C ratings, treat confidence as moderate at best.
- Combinations muddy the picture. The authors highlight combinations containing these peptides. When a product has several actives, you can't tell which ingredient does the work, or whether the mix is what matters.
- "Alternative" isn't "equal." The abstract doesn't report head-to-head results against approved drugs, and a grade B rating doesn't establish that peptides match them.
- The abstract has no numbers. It gives no effect sizes, no hair-count changes and no timelines, so nobody can say how much regrowth to expect.
- Safety is described only in general terms. "Well-tolerated" is the authors' summary, not a detailed safety analysis.
- Everything here is human trial data, which is a strength. But the review is a literature synthesis, not a new trial, and its quality depends on the studies it pooled.
Practical Takeaways
Who might consider these? People with mild thinning who want a low-risk, non-prescription option and accept modest, uncertain results. Anyone with sudden, patchy or rapid hair loss should see a dermatologist first, because the cause matters and the review doesn't address diagnosis.
Using them with minoxidil? The abstract doesn't test peptides combined with minoxidil or any other drug, so there is no evidence-based recommendation either way. Peptide serums are commonly layered into routines alongside established treatments, but ask your dermatologist or pharmacist about sequencing and possible irritation.
- Acetyl Tetrapeptide-3
- Biotinoyl Tripeptide-1
- Copper Tripeptide-1 (GHK-Cu)
- Brand names like Capixyl or Procapil, which are marketing names for ingredient blends
Check the ingredient list for these names, not just front-label claims. Products often use them at unspecified concentrations, and the abstract gives no dose, so there's no verified "effective percentage." Follow the manufacturer's directions rather than guessing.
Timing: The abstract reports no trial durations. Hair grows slowly, so any real test of a product means consistent use over months, not weeks. Take photos under the same lighting to track change honestly.
Bottom Line
This review is a reasonable early map of the peptide hair-loss field. Three ingredients, plus a fourth lesser-known peptide, have enough human trial support to earn a B. That is a step above hype, but well short of settled science. If you try them, treat peptides as a low-risk experiment with modest expectations rather than a replacement for proven treatments, and let a clinician guide you if your hair loss is significant.